Relationship of miRNA-106a and miRNA-20a with severity and prognosis of patients with neonatal respiratory distress syndrome

doi:10.3760/cma.j.issn.1007-1245.2024.19.018

Abstract

Abstract:

Objective　To investigate the correlation of serum levels of microRNA (miRNA)-106a and miRNA-20a with the severity and prognosis of patients with neonatal respiratory distress syndrome (NRDS). Methods　One hundred and fifty-six patients with NRDS treated at Red Cross Hospital, Xi'an Jiaotong University from March 2021 to April 2024 were selected as an NRDS group, including 77 boys and 79 girls whose gestational age was (33.87±2.01) weeks. Based on the chest imaging results, the neonates were divided into a mild group (50 cases), a moderate group (74 cases), and a severe group (32 cases). According to their outcomes, the neonates were classified into a good prognosis group (132 cases) and a poor prognosis group (24 cases). Additionally, 150 healthy preterm infants, including 77 males and 73 females whose gestational age was (34.05±1.83) weeks, were selected as a control group. The serum levels of miRNA-106a and miRNA-20a were measured using quantitative real-time polymerase chain reaction (qPCR). Pearson correlation analysis was used to analyze the relationship of the serum levels of miRNA-106a and miRNA-20a with the Score for Neonatal Acute Physiology, Version Ⅱ (SNAPPE-Ⅱ) and 1-minute Apgar score in the neonates. The predictive values of serum miRNA-106a and miRNA-20a levels for the prognosis of the neonates with NRDS were assessed using the receiver operating characteristic curve (ROC). t and χ² tests were used. Results　The serum levels of miRNA-106a and miRNA-20a in the NRDS group were significantly lower than those in the control group [(0.97±0.30) vs. (1.70±0.53) and (0.88±0.32) vs. (1.57±0.55)], with statistical differences (t=14.750 and 13.346; both P<0.05). There were statistical differences in the serum levels of miRNA-106a and miRNA-20a and the 1-minute Apgar score between the severe group, the moderate group, and the mild group (all P<0.05). Compared with those in the good prognosis group, the serum levels of miRNA-106a and miRNA-20a in the poor prognosis group were lower, and the SNAPPE-Ⅱ score was higher [(0.40±0.19) vs. (1.07±0.36), (0.39±0.17) vs. (0.97±0.34), and (34.25±6.50) vs. (18.10±3.58)], with statistical differences (t=13.438, 12.718, 11.850, all P<0.05). The serum levels of miRNA-106a and miRNA-20a were negatively correlated with the SNAPPE-Ⅱ score (both P<0.05), and positively with the 1-minute Apgar score (both P<0.05). The sensitivity and specificity of miRNA-106a for predicting the poor prognosis in the patients with NRDS were 95.8% and 93.2%, respectively, with an area under the curve (AUC) of 0.961 (95%CI 0.929-0.992); the sensitivity and specificity of miRNA-20a were 91.7% and 89.4%, respectively, with an AUC of 0.938 (95%CI 0.900-0.976). The sensitivity and specificity of the combination of miRNA-106a and miRNA-20a were 91.7% and 97.7%, respectively, with an AUC of 0.984 (95%CI 0.967-1.000), indicating a higher predictive efficacy. Conclusions　The serum levels of miRNA-106a and miRNA-20a are significantly reduced in patients with NRDS, and decrease as the disease severity increases. Both have significant value in predicting the prognosis of patients with NRDS.

Key words:

Neonatal respiratory distress syndrome, MiRNA-106a, MiRNA-20a, Severity, Prognosis

摘要：

目的　探讨血清微小RNA（miRNA）-106a和miRNA-20a水平与新生儿呼吸窘迫综合征（NRDS）严重程度及预后的相关性。方法　选取2021年3月至2024年4月在西安交通大学附属红会医院就诊的156例NRDS患儿为NRDS组，其中男77例，女79例，出生胎龄（33.87±2.01）周。根据NRDS患儿胸部影像检查结果将其分为轻度组（50例）、中度组（74例）和重度组（32例）。根据NRDS患儿结局将其分为预后良好组132例和预后不良组24例。另选取同期在西安交通大学附属红会医院体检的健康早产儿150例作为对照组，其中男77例，女73例，出生胎龄（34.05±1.83）周。采用定量聚合酶链式反应（qPCR）测定血清miRNA-106a和miRNA-20a水平；采用Pearson相关分析NRDS患儿血清miRNA-106a和miRNA-20a水平与新生儿急性生理评分（SNAPPE-Ⅱ）、1 min Apgar评分的相关性；采用受试者操作特征曲线（ROC）评价血清miRNA-106a和miRNA-20a水平预测NRDS患儿预后的价值。采用t检验、χ²检验。结果　NRDS组患儿血清miRNA-106a和miRNA-20a水平低于对照组［（0.97±0.30）比（1.70±0.53）、（0.88±0.32）比（1.57±0.55）］，差异均有统计学意义（t=14.750、13.346，均P<0.05）。重度组、中度组、轻度组血清miRNA-106a和miRNA-20a水平及1 min Apgar评分比较，差异均有统计学意义（均P<0.05）。预后不良组NRDS患儿血清miRNA-106a和miRNA-20a水平低于预后良好组［（0.40±0.19）比（1.07±0.36）、（0.39±0.17）比（0.97±0.34）］，SNAPPE-Ⅱ评分高于预后良好组［（34.25±6.50）分比（18.10±3.58）分］，差异均有统计学意义（t=13.438、12.718、11.850，均P<0.05）。血清miRNA-106a和miRNA-20a水平与SNAPPE-Ⅱ评分呈负相关（均P<0.05），与1 min Apgar评分呈正相关（均P<0.05）。miRNA-106a、miRNA-20a预测NRDS患儿预后不良的灵敏度分别为95.8%、91.7%，特异度分别为93.2%、89.4%，曲线下面积（AUC）分别为0.961（95%CI 0.929～0.992）、0.938（95%CI 0.900～0.976），表明这些生物标志物预测NRDS患儿预后准确度较高。miRNA-106a联合miRNA-20a的灵敏度和特异度分别为91.7%、97.7%，AUC为0.984（95%CI 0.967～1.000），表明联合检测具有更高的预测效能。结论　血清miRNA-106a和miRNA-20a水平在NRDS患儿中降低，且其水平随NRDS患儿严重程度加重而逐渐降低，二者在预测NRDS患儿预后中具有重要价值。

关键词:

新生儿呼吸窘迫综合征, miRNA-106a, miRNA-20a, 严重程度, 预后

Lyu Tao, Wu Wanli.

Relationship of miRNA-106a and miRNA-20a with severity and prognosis of patients with neonatal respiratory distress syndrome [J]. International Medicine and Health Guidance News, 2024, 30(19): 3254-3259.

吕涛伍婉丽.

miRNA-106a和miRNA-20a与新生儿呼吸窘迫综合征严重程度及预后的关系 [J]. 国际医药卫生导报, 2024, 30(19): 3254-3259.

References

[1] 高敏,张楠楠,荣辉,等. 肺部高频超声评分对新生儿呼吸窘迫综合征预测及预后评估的价值[J]. 中国现代医学杂志, 2022, 32(17): 81-87. DOI: 10.3969/j.issn.1005-8982. 2022.17.013.
[2] 郑婉婷,潘石蕾,黄郁馨,等. 晚期早产儿与足月新生儿呼吸窘迫综合征的母体高危因素比较[J]. 广东医学, 2021, 42(7): 773-776. DOI: 10.13820/j.cnki.gdyx.20203127.
[3] 颜林,梅花,刘春枝. 枸橼酸咖啡因治疗新生儿呼吸窘迫综合征的研究进展[J]. 中国小儿急救医学, 2022, 29(9): 721-724. DOI: 10.3760/cma.j.issn.1673-4912. 2022.09.012.
[4] Kim J, Yao F, Xiao Z, et al. MicroRNAs and metastasis: small RNAs play big roles[J]. Cancer Metastasis Rev, 2018, 37(1): 5-15. DOI:10.1007/s10555-017-9712-y.
[5] Zhang C, Sun C, Zhao Y, et al. Overview of microRNAs as diagnostic and prognostic biomarkers for high-incidence cancers in 2021 [J]. Int J Mol Sci, 2022, 23(19): 11389. DOI: 10.3390/ijms231911389.
[6] 王晓丽,梅花,刘春枝. 微小RNAs与新生儿急性呼吸窘迫综合征的研究进展[J]. 中华围产医学杂志, 2019, 22(7): 495-499. DOI: 10.3760/cma.j.issn.1007-9408. 2019.07.013.
[7] Daneshpour M, Ghadimi-Daresajini A. Overview of miR-106a regulatory roles: from cancer to aging[J]. Bioengineering, 2023, 10(8): 892. DOI: 10.3390/bioengineering10080892.
[8] Huang D, Peng Y, Ma K, et al. MiR-20a, a novel promising biomarker to predict prognosis in human cancer: a meta-analysis [J]. BMC Cancer, 2018, 18(1): 1189-1189. DOI: 10.1186/s12885-018-4907-3
[9] Bai Y, Li H, Dong J. Up-regulation of miR-20a weakens inflammation and apoptosis in high-glucose-induced renal tubular cell mediating diabetic kidney disease by repressing CXCL8 expression [J]. Arch Physiol Biochem, 2022, 128(6): 1603-1610. DOI: 10.1080/13813455.2020.1785506.
[10] Zhao H, Gong N. miR-20a regulates inflammatory in osteoarthritis by targeting the IκBβ and regulates NK-κB signaling pathway activation [J]. Biochem Biophys Res Commun, 2019, 518(4): 632-637. DOI: 10.1016/j.bbrc.2019.08.109.
[11] Yuan J, Su Z, Gu W, et al. MiR-19b and miR-20a suppress apoptosis, promote proliferation and induce tumorigenicity of multiple myeloma cells by targeting PTEN [J]. Cancer Biomark, 2019, 24(3): 279-289. DOI: 10.3233/CBM-182182.
[12] You F, Luan H, Sun D, et al. miRNA-106a promotes breast cancer cell proliferation, clonogenicity, migration, and invasion through inhibiting apoptosis and chemosensitivity [J]. DNA Cell Biol, 2019, 38(2): 198-207. DOI: 10.1089/dna.2018.4282.
[13] Li D, Liu L, Du X, et al. MiRNA-374b-5p and miRNA-106a-5p are related to inflammatory bowel disease via regulating IL-10 and STAT3 signaling pathways [J]. BMC Gastroenterol, 2022, 22(1): 492. DOI: 10.1186/s12876-022-02533-1.
[14] Yang J, Chen Y, Jiang K, et al. MicroRNA-106a provides negative feedback regulation in lipopolysaccharide-induced inflammation by targeting TLR4 [J]. Int J Biol Sci, 2019, 15(11): 2308-2319. DOI: 10.7150/ijbs.33432.
[15] Williams GW, Berg NK, Reskallah A, et al. Acute respiratory distress syndrome [J]. Anesthesiology, 2021, 134(2): 270-282. DOI: 10.1097/ALN.0000000000003571.
[16] Hu X, Huang X. Alleviation of inflammatory response of pulmonary fibrosis in acute respiratory distress syndrome by puerarin via transforming growth factor (TGF-β1) [J]. Med Sci Monit, 2019, 25: 6523-6531. DOI: 10.12659/MSM.915570.
[17] 中国医师协会新生儿科医师分会. "新生儿急性呼吸窘迫综合征"蒙特勒标准(2017年版)[J]. 中华实用儿科临床杂志,2017,32(19):1456-1458. DOI: 10.3760/cma.j.issn. 2095-428X.2017.19.004.
[18] 陈成彩, 李丽珍, 钟秋红, 等. 肺超声评分在新生儿呼吸窘迫综合征诊断及病情严重程度评估中的应用价值[J]. 中国超声医学杂志, 2021, 37(9): 989-992. DOI:10.3969/j.issn.1002-0101.2021.09.010.
[19] 陈波, 张惠荣, 段为浩, 等. 两种危重评分对新生儿呼吸窘迫综合征患儿死亡风险的预测价值[J]. 中国现代医学杂志, 2017, 27(3): 97-100. DOI: 10.3969/j.issn.1005-8982. 2017.03.020.
[20] 王丹华. 对Apgar评分的再认识[J]. 中华围产医学杂志, 2021, 24(3): 165-168. DOI: 10.3760/cma.j.cn113903- 20201214-01226.
[21] Marseglia L, D'Angelo G, Granese R, et al. Role of oxidative stress in neonatal respiratory distress syndrome [J]. Free Radic Biol Med, 2019, 142: 132-137. DOI: 10.1016/j.freeradbiomed.2019.04.029.
[22] Hamid ERA, Ali WH, Azmy A, et al. Oxidative stress and anti-oxidant markers in premature infants with respiratory distress syndrome [J]. Open Access Maced J Med Sci, 2019, 7(17): 2858-2863. DOI: 10.3889/oamjms.2019.534.
[23] Cannavò L, Perrone S, Viola V, et al. Oxidative stress and respiratory diseases in preterm newborns [J]. Int J Mol Sci, 2021, 22(22): 12504. DOI: 10.3390/ijms222212504.
[24] Legesse BT, Abera NM, Alemu TG, et al. Incidence and predictors of mortality among neonates with respiratory distress syndrome admitted at West Oromia Referral Hospitals, Ethiopia, 2022. Multi-centred institution based retrospective follow-up study [J]. PLoS One, 2023, 18(8): e0289050. DOI: 10.1371/journal.pone.0289050.
[25] Kočović AG, Kostić GD, Savić DM, et al. Factors associated with the occurrence of death outcome in children with neonatal respiratory distress syndrome[J]. Experimental and Applied Biomedical Research (EABR), 2021, 22(1): 51-57. DOI: 10.2478/sjecr-2019-0031.
[26] Mohamed HA, Abdelkafy AE, Khairy RMM, et al. MicroRNAs and cytokines as potential predictive biomarkers for COVID-19 disease progression [J]. Sci Rep, 2023, 13(1): 3531. DOI: 10.1038/s41598-023-30474-6.